Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COWBOY trial of targeted induction before ipilimumab + nivolumab in BRAF V600-mutant melanoma with elevated LDH
NL-OMON48120Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vemurafenib, cobimetinib, ipilimumab and nivolumab in melanoma and cutaneous malignancy (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Best overall response rate. Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON48120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48120.